U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06943534) titled 'Omalizumab Weight-Based Dosing Efficacy Trial' on March 28.
Brief Summary: This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
Study Start Date: April 28
Study Type: INTERVENTIONAL
Condition:
Allergies
Food Allergy
Intervention:
DRUG: 5mg/kg omalizumab injection
5mg/kg of omalizumab
DRUG: 15mg/kg omalizumab injection
15mg/kg of omalizumab
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Massachusetts General Hospital
Information provided by (Responsible Party): Wayne G. Shreffler, MD, PhD, Massachusetts General Hospital
Disclaimer: Curated by HT S...